Revised Document Posted: NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012, 38297 [2012-15651]

Download as PDF Federal Register / Vol. 77, No. 124 / Wednesday, June 27, 2012 / Notices HHS/CDC has posted the original notice and all related materials on www.regulations.gov. Dated: June 20, 2012. Kathleen Sebelius, Secretary, Department of Health and Human Services. [FR Doc. 2012–15642 Filed 6–26–12; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket Number NIOSH–033–A] Revised Document Posted: NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012 National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of issuance of Final Guidance Publication. AGENCY: srobinson on DSK4SPTVN1PROD with NOTICES Dated: June 20, 2012. John Howard, Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. [FR Doc. 2012–15651 Filed 6–26–12; 8:45 am] The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the publication of the following document entitled ‘‘NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.’’ NIOSH is making available a copy of Appendix A at https:// www.cdc.gov/niosh/docs/2012-150. Background: The NIOSH Alert: NIOSH published Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings in September 2004 (https://www.cdc.gov/ niosh/docs/2004-165/). Appendix A of this Alert defined hazardous drugs and provided a list of drugs that were considered hazardous and required special handling. In 2010, NIOSH published an update to this list (https://www.cdc.gov/niosh/docs/2010167/). Since publishing the 2010 update to the list, NIOSH reviewed approximately 70 new drugs that received FDA approval and approximately 180 drugs that received new special warnings (usually black box warnings) based on reported adverse effects in patients covering the time period from October 2007 to December 2009. From this list of approximately 250 drugs, NIOSH determined 26 drugs to have one or more characteristics of a hazardous drug. In addition, NIOSH removed 15 drugs from the 2012 list SUMMARY: VerDate Mar<15>2010 19:05 Jun 26, 2012 Jkt 226001 because they did not meet the NIOSH definition, were no longer available in the U.S or were regulated by other government entities. NIOSH published this preliminary list for comment in NIOSH Docket Number 190. After expert panel review, public review and comment, and review of the scientific literature, NIOSH has developed a revised list of hazardous drugs. Along with drugs initially identified in the 2010 Hazardous Drug List, NIOSH is adding a total of 26 new drugs to the 2012 NIOSH List of Hazardous Drugs and is deleting 15 drugs. This guidance document does not have the force and effect of law. FOR FURTHER INFORMATION CONTACT: Barbara MacKenzie, NIOSH, Robert A. Taft Laboratories, 4676 Columbia Parkway, MS–C26, Cincinnati, OH 45226, Telephone (513) 533–8132, email hazardousdrugs@cdc.gov. BILLING CODE 4163–19–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [Document Identifier CMS–359 and –360] Agency Information Collection Activities: Proposed Collection; Comment Request Centers for Medicare & Medicaid Services, HHS. In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Centers for Medicare & Medicaid Services (CMS) is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency’s functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden. AGENCY: PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 38297 1. Type of Information Collection Request: Extension without change of a currently approved collection. Title of Information Collection: Comprehensive Outpatient Rehabilitation Facility (CORF) Eligibility and Survey Forms. Use: CMS–359 serves as the application for facilities wishing to participate in the Medicare/Medicaid program as CORFs. The form initiates the process for obtaining a decision as to whether the conditions of participation are met. It also promotes data reduction (key punching) or introduction to and retrieval from the Medicare/Medicaid Automated Certification System, ASPEN, by the CMS Regional Offices (ROs). Should any question arise regarding the structure of the organization, this information is readily available without going through the process of completing the form again. CMS–360 is used by the State survey agency to record data collected to determine provider compliance with individual conditions of participation and to report it to the Federal government. CMS has the responsibility and authority for certification decisions which are based on provider compliance with the conditions of participation. The information needed to make these decisions is available to CMS only through use of information abstracted from the survey checklists. The form is primarily a worksheet designed to facilitate keypunching into the ASPEN by the State Agency after the survey is completed. Form Number: CMS–359 (CORF Eligibility Form) and CMS–360 (CORF Survey Report Form); OCN 0938–0267. Frequency: Occasionally. Affected Public: Private Sector (Business or other for-profits). Number of Respondents: 295. Total Annual Responses: 42. Total Annual Hours: 137. (For policy questions regarding this collection contact Georgia Johnson at 410–786– 6859. For all other issues call 410–786– 1326.) To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access CMS’ Web Site address at https://www.cms.hhs.gov/ PaperworkReductionActof1995, or Email your request, including your address, phone number, OMB number, and CMS document identifier, to Paperwork@cms.hhs.gov, or call the Reports Clearance Office on (410) 786– 1326. In commenting on the proposed information collections please reference the document identifier or OMB control number. To be assured consideration, comments and recommendations must E:\FR\FM\27JNN1.SGM 27JNN1

Agencies

[Federal Register Volume 77, Number 124 (Wednesday, June 27, 2012)]
[Notices]
[Page 38297]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-15651]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket Number NIOSH-033-A]


Revised Document Posted: NIOSH List of Antineoplastic and Other 
Hazardous Drugs in Healthcare Settings 2012

AGENCY: National Institute for Occupational Safety and Health (NIOSH) 
of the Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of issuance of Final Guidance Publication.

-----------------------------------------------------------------------

SUMMARY: The National Institute for Occupational Safety and Health 
(NIOSH) of the Centers for Disease Control and Prevention (CDC) 
announces the publication of the following document entitled ``NIOSH 
List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 
2012.'' NIOSH is making available a copy of Appendix A at https://www.cdc.gov/niosh/docs/2012-150.
    Background: The NIOSH Alert: NIOSH published Preventing 
Occupational Exposures to Antineoplastic and Other Hazardous Drugs in 
Health Care Settings in September 2004 (https://www.cdc.gov/niosh/docs/2004-165/). Appendix A of this Alert defined hazardous drugs and 
provided a list of drugs that were considered hazardous and required 
special handling. In 2010, NIOSH published an update to this list 
(https://www.cdc.gov/niosh/docs/2010-167/). Since publishing the 2010 
update to the list, NIOSH reviewed approximately 70 new drugs that 
received FDA approval and approximately 180 drugs that received new 
special warnings (usually black box warnings) based on reported adverse 
effects in patients covering the time period from October 2007 to 
December 2009. From this list of approximately 250 drugs, NIOSH 
determined 26 drugs to have one or more characteristics of a hazardous 
drug. In addition, NIOSH removed 15 drugs from the 2012 list because 
they did not meet the NIOSH definition, were no longer available in the 
U.S or were regulated by other government entities. NIOSH published 
this preliminary list for comment in NIOSH Docket Number 190.
    After expert panel review, public review and comment, and review of 
the scientific literature, NIOSH has developed a revised list of 
hazardous drugs. Along with drugs initially identified in the 2010 
Hazardous Drug List, NIOSH is adding a total of 26 new drugs to the 
2012 NIOSH List of Hazardous Drugs and is deleting 15 drugs.
    This guidance document does not have the force and effect of law.

FOR FURTHER INFORMATION CONTACT: Barbara MacKenzie, NIOSH, Robert A. 
Taft Laboratories, 4676 Columbia Parkway, MS-C26, Cincinnati, OH 45226, 
Telephone (513) 533-8132, email hazardousdrugs@cdc.gov.

    Dated: June 20, 2012.
John Howard,
Director, National Institute for Occupational Safety and Health, 
Centers for Disease Control and Prevention.
[FR Doc. 2012-15651 Filed 6-26-12; 8:45 am]
BILLING CODE 4163-19-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.